Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial-Reference-Cited by-同舟云学术

Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial

Published:2020-01 Issue: Volume:88 Page:106283
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Jabbour Elias^ORCID,Gökbuget Nicola,Advani Anjali,Stelljes Matthias,Stock Wendy,Liedtke Michaela,Martinelli Giovanni,O’Brien Susan,Wang Tao,Laird A. Douglas,Vandendries Erik,Neuhof Alexander,Nguyen Kevin,Dakappagari Naveen,DeAngelo Daniel J.,Kantarjian Hagop

Funder

Pfizer

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference30 articles.

1. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL);Bassan;Blood,2009

2. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis;Berry;JAMA Oncol.,2017

3. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies;Gokbuget;Blood,2012

4. Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993;Patel;Br. J. Haematol.,2010

5. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia;Ravandi;Br. J. Haematol.,2016

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prediction of Response to FDA-Approved Targeted Therapy and Immunotherapy in Acute Lymphoblastic Leukemia (ALL);Current Treatment Options in Oncology;2024-08-05

2. Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions;Cancer;2024-08-02

3. Treatment of Relapsed Acute Lymphocytic Leukemia in Adult Patients;Current Treatment Options in Oncology;2024-06-25

4. Inotuzumab ozogamicin as a bridging therapy to allogeneic hematopoietic stem cell transplantation in children with refractory/relapsed B-cell acute lymphoblastic leukemia;Pediatric Hematology/Oncology and Immunopathology;2024-05-14

5. Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions;Journal of Hematology & Oncology;2024-05-11